The Clinical Observation Of Fluorouracil Sustained-release Implants In The Treatment Of Malignant Body Cavity Fluid

Background:Malignant body cavity effusions are common complications in patients with advanced。it could seriously affect the quality of life and prognosis of patients. Although there are many clinical treatment methods used ,but for the majority of patients with malignant effusion,it could only alleviate symptoms temporarily because of it′s high relapse rate. Fluorouracil sustained-release implants is a new dosage formulations. After implantation in the body cavity ,it could release slowly,maintain the effective drug concentration for long time。Because of its localized delivery, its blood concentration is very low that could significantly reduced systemic toxicity.Objective: In view of several studies which have been carried out preliminary showed benefit in the treatment of malignant body cavity effusion, especially in palliative care. This topics tend to study the efficiency and safety of this drug about the treatment of malignant body cavity furthermore, expanding populations, increaseing numbers of observed indicators, improving the clinical understanding of the drug as possible as we could. At the same time because of the patients with malignant body cavity effusion almost in advanced stage. Palliative care maybe its main purpose, So our subject is particular to observe several relevant indicators about the quality of life.Methods: A survey was undertaken on malignant body cavity effusion patients in the department of oncology, the first affiliated hospital of Anhui Medical University and Xin'an provincial hospital from the October 2006 to October 2007。Injected Sustained-release implants fluorouracil with 800mg/ m2 into their body cavity。Then evaluate its efficiency with the criteria which proposed by Millar JW et ,evaluate their quality of life with KPS and fatigue symptom scale, evaluation of its toxicity with CTCAE3.0。And to observe the influence with different kinds of disease, baseline KPS score, tumor markers and cytology.Results: there are 52 patients suitable for admission , of which 22 cases of male, female 30 cases. Tumor types include 18 cases of ovarian cancer, 13 cases of lung cancer, 21 cases of unknown primary tumors and other types of tumors. And all patients were re-treated cases. Malignant body cavity effusions total remission rate is 52%. The remission of Ovarian cancer ascites rate is 67 percent, significantly higher than others. the remission rate of patients with effusion positive cytology is 66%, also significantly higher than those with negative cytology. And baseline KPS score, tumor markers had no significant impact on the efficacy. KPS scores in patients are markedly improved after treatment , the treatment did not increase the patient's fatigue. All the patients had no significant toxicity (Ⅲ-Ⅳ).Conclusion: Sustained-release implants fluorouracil can obtain a better clinical efficacy in the treatment of malignant body cavity body cavity effusion, especially on the effect of ovarian cancer ascites. The remission rate of Body cavity effusions have something relevant with primary tumor types, effusion cytology relevant. And baseline KPS score, tumor marker has nothing to do. The drug can significantly improve the quality of life of patients and minimize side effects. Maybe it could become a new method about the treatment of malignant body cavity effusion.